Safeguard Scientifics, Inc.

SFES · Other OTC · USD

0,63USD

+0,03 (+5,00 %)Stand 9. Nov., 21:00

Vortag 0,60

Kennzahlen

Eröffnung
0,59
Vortag
0,60
Tagesspanne
0,59 – 0,63
52 Wochen
0,22 – 1,89
Volumen
2000
Ø Volumen
14.442
Börsenwert
10,54 Mio. $
KGV
0,5
Gewinn je Aktie (TTM)
1,17
Dividendenrendite
222,2 %
Beta
-0,9
Nächste Zahlen
10. Nov. 2026

Finanzen

USDFY 2025FY 2024FY 2023FY 2022FY 2021
Umsatz00000
Herstellungskosten436.000374.000319.000271.000229.000
Bruttogewinn−436.000−374.000−319.000−271.000−229.000
Forschung und Entwicklung00000
Vertrieb und Verwaltung1,66 Mio.2,25 Mio.5,36 Mio.4,78 Mio.7,15 Mio.
Operatives Ergebnis−2,1 Mio.−2,63 Mio.−5,68 Mio.−4,78 Mio.−7,15 Mio.
EBITDA−1,66 Mio.−10,01 Mio.−9,51 Mio.−13,99 Mio.27,23 Mio.
Nettogewinn1,73 Mio.−10,39 Mio.−9,83 Mio.−14,26 Mio.27 Mio.
Gewinn je Aktie (verwässert)0,10-0,62-0,61-0,871,36

Bewertung

Letzte 12 Monate

KGV
0,5
Kurs-Umsatz-Verhältnis
0,0
Kurs-Buchwert-Verhältnis
1,7
PEG
0,0
Bruttomarge
0,0 %
Operative Marge
0,0 %
Nettomarge
0,0 %
Verschuldungsgrad
0,0
EV/EBITDA
-3,0
Eigenkapitalrendite
130,9 %
Kapitalrendite (ROIC)
−30,1 %
Free-Cashflow-Rendite
0,0 %
FY 2025FY 2024FY 2023FY 2022FY 2021
Bruttomarge0,0 %0,0 %0,0 %0,0 %0,0 %
Operative Marge0,0 %0,0 %0,0 %0,0 %0,0 %
Nettomarge0,0 %0,0 %0,0 %0,0 %0,0 %
KGV8,0-1,4-1,3-3,65,4
Kurs-Umsatz-Verhältnis0,00,00,00,00,0
Kurs-Buchwert-Verhältnis1,21,50,61,52,9
Verschuldungsgrad0,00,10,10,00,0
Liquidität 3. Grades10,15,84,811,817,5
Dividendenrendite0,0 %0,0 %46,0 %0,0 %0,0 %
Unternehmenswert4,68 Mio.8,28 Mio.4,4 Mio.38,99 Mio.123,04 Mio.
EV/EBITDA-2,8-0,8-0,5-2,84,5
Eigenkapitalrendite14,9 %−105,7 %−49,2 %−41,3 %53,4 %
Kapitalrendite (ROIC)−17,8 %−24,7 %−26,7 %−13,2 %−13,6 %
Free-Cashflow-Rendite0,0 %−20,8 %−26,1 %−6,4 %−5,6 %

Wachstum

FY 2025FY 2024FY 2023FY 2022FY 2021
Umsatz0,0 %0,0 %0,0 %0,0 %0,0 %
Bruttogewinn−16,6 %−17,2 %−17,7 %−18,3 %+26,4 %
Operatives Ergebnis+20,1 %+53,8 %−19,0 %+33,2 %+24,4 %
Nettogewinn+116,6 %−5,7 %+31,1 %−152,8 %+171,8 %
Gewinn je Aktie+116,1 %−1,6 %+29,9 %−164,0 %+175,1 %
Freier Cashflow0,0 %+10,0 %−1,5 %+60,0 %−0,1 %
Dividende je Aktie0,0 %−100,0 %0,0 %0,0 %0,0 %

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Schätzungen

FY 2026FY 2027FY 2028
Umsatz (Ø)000
Umsatz (Tief – Hoch)0 – 00 – 00 – 0
Gewinn je Aktie (Ø)-3,52-1,270,09
Gewinn je Aktie (Tief – Hoch)-3,52 – -3,52-1,27 – -1,270,09 – 0,09
Analysten111

Quartalszahlen

Nächste Zahlen: 10. Nov. 2026
Aug. 2026Mai 2026März 2026Nov. 2025Aug. 2025Apr. 2025März 2025Nov. 2024
Gewinn je Aktie · Erwartet-0,27-0,29-0,29-0,34––––
Gewinn je Aktie · Tatsächlich-0,021,10-0,020,100,07-0,33-0,33-0,07
Abweichung+92,59 %+479,31 %+94,07 %+129,41 %––––
Umsatz · Tatsächlich––––––––

Dividenden und Splits

Ex-TagZahltagBetrag
21. Apr. 2026–1,40
29. Dez. 2023–0,35
20. Dez. 2019–1,00
3. Juli 1997–2,70

Aktiensplits

  • 27. Aug. 20091:6
  • 20. März 20003:1
  • 1. Aug. 19962:1
  • 15. Sept. 19953:2
  • 15. Sept. 19942:1

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

  • StepStone Group Holdings LLC6. Dez. 2013 · 10 percent ownerKauf5,61 Mio. Aktien
  • StepStone Group Holdings LLC6. Dez. 2013 · 10 percent ownerVerkauf561.155,5 Aktien
  • SLATTERY JOSEPH P2. Okt. 2013 · officer: EVP and CFOKauf1 Mio. Aktien
  • SLATTERY JOSEPH P2. Okt. 2013 · officer: EVP and CFOVerkauf0 Aktien · 0,40
  • StepStone Group Holdings LLC3. Sept. 2013 · 10 percent ownerVerkauf0 Aktien
  • StepStone Group Holdings LLC3. Sept. 2013 · 10 percent ownerVerkauf0 Aktien
  • StepStone Group Holdings LLC3. Sept. 2013 · 10 percent ownerVerkauf0 Aktien
  • SVLSF IV, LLC3. Sept. 2013 · 10 percent ownerVerkauf0 Aktien

Vergleichbare Unternehmen

Über das Unternehmen

Safeguard Scientifics, Inc., a former private equity and venture capital firm, is no longer actively seeking new investments. Historically, the firm specialized in a broad range of financing activities, including providing capital for company expansion and growth, facilitating management buyouts, executing recapitalizations, driving industry consolidations, and supporting corporate spin-offs. Their investment scope covered both early and growth-stage companies. Typically, Safeguard Scientifics participated in Series A, B, or C funding rounds, with an opportunistic approach to seed-stage investments. Their primary sector focus spanned technology, financial services, and healthcare. Within the technology sphere, their interests were diverse, encompassing areas such as software-as-a-service (SaaS), adtech, digital media, the Internet of Everything (IoE), advanced security solutions, predictive analytics, machine learning, artificial intelligence, enterprise software, technology-enabled services, internet/new media, financial technology (FinTech), cloud computing, mobile, social platforms, big data, in-memory computing, and select business services. For these tech ventures, they considered companies requiring up to $25 million in capital. In the healthcare sector, the firm directed its investments towards molecular and point-of-care diagnostics, various medical devices, regenerative medicine, broader medical technology, digital health solutions, healthcare technology, specialized pharmaceuticals, and chosen healthcare services. Geographically, Safeguard Scientifics invested across the entire United States, with a particular emphasis on the Mid-Atlantic region, and also extended its reach into Southeastern Canada. Financial commitments for growth equity financing generally ranged from $5 million to $25 million, while early-stage financings typically saw investments between $5 million and $10 million. The firm's investment strategy often targeted a variety of capital structures, including self-funded (bootstrapped) companies, corporate divisions or business units, and venture capital-backed entities seeking a growth partner. Safeguard Scientifics aimed to be the largest stakeholder in its portfolio companies, typically acquiring an ownership stake between 20% and 50%, though they were flexible and might occasionally take either a majority or a smaller interest. A strong preference existed for companies possessing proprietary technology and intellectual property. Furthermore, the firm routinely sought a Board seat in its invested companies. Founded in 1953 as Lancaster Corporation, the company adopted the name Safeguard Scientifics, Inc. in 1981. Its main office is located in Radnor, Pennsylvania, with an additional presence in Weston, Massachusetts.

Führung

  • G. Matthew BarnardGeneral Counsel, Secretary & Compliance Officer
  • Mark R. DowChief Executive Officer, Chief Financial Officer & Company Secretary
  • Seth ZuckermanSenior Associate of Healthcare
  • Alex A. FuiksAssociate
CEO
Mark R. Dow
Mitarbeitende
33
Hauptsitz
Radnor, PA, US
Sektor
Financial Services
Branche
Asset Management
Börsengang
17. März 1980

Nachrichten

Gerade keine Nachrichten zu diesem Unternehmen.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.